2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2367

Risk of Malignancy in Dermatomyositis with Anti-CADM-140/ Melanoma Differentiation- Associated Gene 5 Autoantibody
Abstract Number: 1975

Risk of Mortality of Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Abstract Number: 1507

Risk of Obstructive Sleep Apnea in Rheumatoid Arthritis Patients: The Frequency and Associated Disease Features
Abstract Number: 2232

Risk of Osteoporotic Fractures with Use of Cyclooxygenase-2 Inhibitors
Abstract Number: 886

Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Abstract Number: 567

Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
Abstract Number: 1569

Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Abstract Number: 277

Rituximab in Refractory Mixed Connective Tissue Disease: An Observational Study
Abstract Number: 2362

Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Abstract Number: 751

Rituximab Induced Serum Sickness: A Systematic Review
Abstract Number: 615

Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells
Abstract Number: 3234

Roadblocks Perceived By Canadian Dermatologists for Referring Patients with Suspected Psoriatic Arthritis
Abstract Number: 3032

Role of Adenosine and Neutrophils in Inflammation Associated with Mutations in CECR1 Gene
Abstract Number: 1625

Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of ANTI-CCPS in the Phenotypic Switching and the Insulin Signalling
Abstract Number: 3008

Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].